India, Aug. 11 -- Protara Therapeutics, Inc. (TARA), a clinical-stage biotechnology company focused on therapies for cancer and rare diseases, reported its second-quarter 2026 financial results and provided a business update, with investors focusing on progress across TARA-002, IV Choline Chloride and upcoming clinical and regulatory milestones.
Recent Business & Clinical Updates:
Protara expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial evaluating TARA-002 in non-muscle invasive bladder cancer (NMIBC) in the fourth quarter of 2026.
The company is redesigning the ADVANCED-3 trial as a multi-cohort, open-label exploratory study to evaluate TARA-002 in broader high-grade, high-risk NMIBC populations, inc...